natgillin/translations-raw huggingface dataset:
Invirase, taken in combination with other antiviral medicines, resulted in a reduction of the viral loads and improvements in the immune system.
Pokazalo se da lijek Invirase, u kombinaciji s drugim antivirusnim lijekovima, smanjuje virusno opterećenje i poboljšava imunosni sustav.
Invirase/ritonavir and ergot alkaloids
Invirase/ritonavira i ergot
Invirase/ritonavir and other proton
inhibitora protonske pumpe.
Invirase/ritonavir due to potentially
lijekovima Invirase/ritonavir zbog
Invirase/ritonavir due to potentially
s lijekovima Invirase/ritonavir
Invirase/ritonavir due to the potential
Fusidatna kiselina (sakvinavir/ritonavir)
Invirase/ritonavir is contraindicated in patients with decompensated hepatic impairment (see sections 4.3 and 4.4).
Invirase/ritonavir su kontraindicirani u bolesnika s dekompenziranim oštećenjem jetre (vidjeti dijelove 4.3 i 4.4).
Invirase/ritonavir may increase
Lijekovi Invirase/ritonavir mogu
Invirase/ritonavir may increase ergot
Invirase/ritonavir mogu povećati
Invokana 100 mg film-coated tablets (tablets) are yellow, capsule-shaped, 11 mm long, with “CFZ” on one side and “100” on the other side.
Invokana 100 mg filmom obložene tablete (tablete) su žute, oblika poput kapsule, dužine 11 mm, s “CFZ” na jednoj strani i “100” na drugoj strani.
Invokana 100 mg film-coated tablets EU/1/13/884/001 (10 tablets) EU/1/13/884/002 (30 tablets) EU/1/13/884/003 (90 tablets) EU/1/13/884/004 (100 tablets)
Invokana 100 mg filmom obložene tablete EU/1/13/884/001 (10 tableta) EU/1/13/884/002 (30 tableta) EU/1/13/884/003 (90 tableta) EU/1/13/884/004 (100 tableta)
Invokana 300 mg film-coated tablets (tablets) are white, capsule-shaped, 17 mm long, with “CFZ” on one side and “300” on the other side.
Invokana 300 mg filmom obložene tablete (tablete) su bijele, oblika poput kapsule, dužine 17 mm, s “CFZ” na jednoj strani i “300” na drugoj strani.
Invokana 300 mg film-coated tablets EU/1/13/884/005 (10 tablets) EU/1/13/884/006 (30 tablets) EU/1/13/884/007 (90 tablets) EU/1/13/884/008 (100 tablets)
Invokana 300 mg filmom obložene tablete EU/1/13/884/005 (10 tableta) EU/1/13/884/006 (30 tableta) EU/1/13/884/007 (90 tableta) EU/1/13/884/008 (100 tableta)
Invokana can also be used as an ‘add-on’ to other diabetes medicines, including insulin, when these medicines together with exercise and diet are not providing adequate control of the diabetes.
Invokana se može koristiti kao dodatna terapija uz druge lijekove, uključujući inzulin, kada oni zajedno s dijetom i tjelovježbom nisu dostatni za primjerenu kontrolu dijabetesa.
Invokana contains lactose
Invokana sadrži laktozu
Invokana contains the active substance canagliflozin which belongs to a group of medicines called “blood-glucose lowering drugs.”
Invokana sadrži djelatnu tvar kanagliflozin koja pripada skupini lijekova koji se nazivaju “lijekovi za snižavanje šećera u krvi.”
Invokana is not recommended for children and adolescents under 18 years.
Primjena lijeka Invokana se ne preporučuje u djece i adolescenata ispod 18 godina.
Invokana should not be used to treat this condition. if you experience rapid weight loss, feeling sick or being sick, stomach pain, excessive thirst, fast and deep breathing, confusion, unusual sleepiness or tiredness, a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat, contact a doctor or the nearest hospital straight away.
Invokana se ne smije uzimati za liječenje ovog stanja. ako iskusite nagli gubitak tjelesne težine, osjećaj mučnine ili povraćanje, bol u trbuhu, prekomjernu žeđ, ubrzano i duboko disanje, smetenost, neuobičajenu pospanost ili umor, zadah slatkog mirisa, slatki ili metalni okus u ustima ili drugačiji miris mokraće ili znoja, odmah se javite liječniku ili u najbližu bolnicu.
Involuntary eye movement (nystagmus)
Nevoljna kretnja oka (nistagmus)
involuntary loss of urine (incontinence),
nemogućnost kontroliranja mokrenja (inkontinencija),
involuntary loss of urine (incontinence), difficulty in passing urine
nevoljno mokrenje (inkontinencija), otežano mokrenje
involuntary movement (dyskinesia),
nevoljni pokreti (diskinezija),
Involuntary muscle contraction (convulsions).
nevoljno stezanje mišića (konvulzije).
involuntary muscle contractions
nevoljno stezanje mišića
Involuntary muscle movements, twitching or spasms
nevoljni mišićni pokreti, trzaji ili grčevi
involuntary muscle spasms (convulsion)
nehotični mišićni grčevi (konvulzija)
involuntary shaking movement
nevoljni drhtavi pokreti
Involuntary urination
nevoljno mokrenje
involuntary, irregular muscle movements, especially in the face
nevoljne, nepravilne mišićne pokrete, osobito na licu
involuntary, irregular muscle movements, especially in the face
nevoljni, nepravilni pokreti mišića, osobito lica
Involved in Transactional Sex Last 6 Month, N (%)
Bavili se transakcijskim seksom u zadnjih 6 mjeseci, N (%)
IOA 2.5 mg/1.5 mg film-coated tablets
IOA 2,5 mg/1,5 mg filmom obložene tablete
IOA contains 17β-estradiol.
IOA sadrži 17-estradiol.
IOA contains lactose
IOA sadrži laktozu
IOA is indicated for the prevention of pregnancy.
IOA je indiciran za sprječavanje trudnoće.
IOA may also interfere with the working of other medicines – such as the anti-epileptic lamotrigine.
IOA također može ometati djelovanje drugih lijekova - poput antiepileptika lamotrigina.
IOA, like other hormonal contraceptives, does not protect against HIV infection (AIDS) or any other sexually transmitted disease.
IOA, kao ni drugi hormonski kontraceptivi, ne štiti od infekcije HIV-om (AIDS) ili bilo koje druge spolno prenosive bolesti.
Iodinated contrast agents
Jodna kontrastna sredstva
Iodinated contrast agents
Kontrastna sredstva na bazi joda
iodinated contrast agents or alcohol-containing medicines
kontrastna sredstva koja sadrže jod ili lijekovi koji sadrže alkohol
iodine contrast media (agents used for imaging examinations). arthritis medicines.
jodna kontrastna sredstva (sredstva koja se koriste za pretrage snimanjem). lijekove za liječenje artritisa.
iodine contrast media (agents used for imaging examinations);
jodnim kontrastnim sredstvima (sredstva koja se koriste za pretrage snimanjem);
Iodine contrasting agents: In case of diuretic-induced dehydration, there is an increased risk of acute renal failure, especially with high doses of iodine products.
Jodna kontrastna sredstva: U slučaju dehidracije izazvane diuretikom postoji povećan rizik od akutnog zatajenja bubrega, posebno kod primjene visokih doza sredstava s jodom.
Iodine salts and/or levothyroxine.
soli joda i/ili levotiroksina.
Ioflupane (123I) is cleared rapidly from the blood after intravenous injection; only 5% of the administered activity remains in whole blood at 5 minutes post-injection.
Ioflupan (123I) se nakon intravenske injekcije brzo uklanja iz krvi; 5 minuta nakon injekcije u cijeloj krvi preostaje samo 5% primjenjene aktivnosti.
Ioflupane also binds to the serotonin transporter on 5-HT neurons but with lower (approximately 10-fold) binding affinity.
Ioflupan se također veže na prijenosnik serotonina na 5-HT neuronima ali s manjim (otprilike 10 puta) afinitetom vezanja.
iol/
diol/
Ion exchange resins Absorption of thiazide diuretics, including hydrochlorothiazide, is decreased by cholestyramine or colestipol.
Kolestiramin ili kolestipol smanjuju apsorpciju tiazidnih diuretika, uključujući hidroklorotiazid.
Ion exchange resins: Absorption of thiazide diuretics, including hydrochlorothiazide, is decreased by cholestyramine or colestipol.
Ionske-izmjenjivačke smole: Kolestiramin ili kolestipol smanjuju apsorpciju tiazidnih diuretika, uključujući hidroklorotiazid.
ion, sudden death (see section 4.4)11
iznenadna smrt (vidjeti dio 4.4)11
ION-2 was a randomised, open-label study that evaluated 12 and 24 weeks of treatment with ledipasvir/sofosbuvir with or without ribavirin (randomised 1:1:1:1) in genotype 1 HCV-infected patients with or without cirrhosis who failed prior therapy with an interferon-based regimen, including regimens containing an HCV protease inhibitor.
ION-2 bilo je randomizirano, otvoreno ispitivanje kojim se procijenilo 12 i 24 tjedna liječenja ledipasvirom/sofosbuvirom s ribavirinom ili bez njega u pacijenata (randomiziranih u omjeru 1:1:1:1) s cirozom ili bez nje zaraženih genotipom 1 HCV-a u kojih je prethodna terapija režimom na temelju interferona bila neuspješna, uključujući režime koji su sadržavali inhibitor proteaze HCV-a.
IONSYS 40 micrograms per dose transdermal system
IONSYS 40 mikrograma po dozi transdermalni sustav
IONSYS 40 micrograms per dose transdermal system Fentanyl
IONSYS 40 mikrograma po dozi transdermalni sustav Fentanil
IONSYS DEVICE
UREĐAJ IONSYS
IONSYS Instructions for Use and Disposal
Upute za primjenu i zbrinjavanje lijeka IONSYS
IONSYS is a transdermal system and is made up of an electronic controller (the top housing) and a drug unit (the red bottom housing).
IONSYS je transdermalni sustav i sastoji se od elektroničkog kontrolera (gornje kućište) i odjeljka s lijekom (crveno donje kućište).
IONSYS is designed so that you can’t use too much, provided that only you operate it, and that only you use it when you need pain relief.
IONSYS je izrađen tako da ga ne možete primijeniti previše, uz uvjet da ga samo Vi koristite i to samo kada trebate ublažiti bol.
IONSYS is indicated for the management of acute moderate to severe post-operative pain in adult patients.
IONSYS je indiciran za liječenje akutne umjerene do teške postoperativne boli u odraslih bolesnika.
IONSYS is ready to be used again and you may start another dose at any time you need it.
IONSYS je spreman za ponovno korištenje i možete započeti drugu dozu kad god Vam je potrebna.
IONSYS should also be removed prior to a magnetic resonance imaging (MRI) procedure, X-ray or CT scan.
IONSYS se također treba ukloniti prije postupka snimanja magnetskom rezonancijom (MR), RTG-a ili CT-a.
IONSYS should also not be placed on skin on which topical medicines have been applied.
IONSYS se također ne smije stavljati na kožu na kojoj su primijenjeni topikalni lijekovi.
IONSYS should be administered with caution to patients with moderate or severe hepatic or renal impairment (see section 4.4).
IONSYS je potrebno primjenjivati uz oprez u bolesnika s umjerenim ili teškim oštećenjem funkcije jetre ili bubrega (vidjeti dio 4.4).
IONSYS should be used with caution in patients with hearing impairment who might not be able to hear the audible signals from the system.
IONSYS je potrebno koristiti uz oprez u bolesnika s oštećenjem sluha koji možda ne čuju zvučne signale sustava.
IONSYS should not be placed on abnormal skin sites, such as scars, burns, tattoos, etc.
IONSYS se ne smije stavljati na mjesta s kožnim promjenama, kao što su ožiljci, opekline, tetovaže itd.
IONSYS Troubleshooting
Rješavanje problema na sustavu IONSYS
IONSYS was also evaluated in four active-control trials (predominantly female (65%), Caucasian (85%), with a mean age of 55 years (range, 18-91 years), and primarily comprised of surgeries including lower abdominal and orthopedic bone procedures) using a standard intravenous patient controlled analgesia (PCA) morphine regimen as the comparator.
IONSYS je također procijenjen u četiri ispitivanja s aktivnom kontrolom (pretežno ženski ispitanici (65%), bijelci (85%), srednje vrijednosti dobi 55 godina (raspon 18-91 godina) koja su se primarno sastojala od kirurških zahvata koji su uključivali postupke na donjem abdomenu i ortopedske postupke na kostima) uz primjenu morfina kao standardne intravenske analgezije koju nadzire bolesnik (engl. patient controlled analgesia, PCA) kao lijek usporedbe.
IONSYS will ignore any button presses during the 10-minute dosing period.
IONSYS će zanemariti bilo koji pritisak na dugme tijekom 10-minutnog razdoblja doziranja.
IONSYS will stop working after one day (24 hours) or after 80 doses have been delivered, whichever one comes first.
IONSYS će prestati raditi nakon jednog dana (24 sata) ili nakon što isporuči 80 doza, što god nastupi prije.
IOP was measured in ‘millimetres of mercury’ (mmHg).
IOP je izmjeren u „milimetrima žive” (mmHg).
IPD
IPB
IPD due to individual serotypes(4)
IPB izazvan pojedinačnim serotipovima(4)
IPD Invasive Pneumococcal Disease
IPB invazivna pneumokokna bolest
IPF is a chronic fibrotic and inflammatory pulmonary disease affected by the synthesis and release of pro-inflammatory cytokines including tumour necrosis factor-alpha (TNF-α) and interleukin-1-beta (IL-1β) and pirfenidone has been shown to reduce the accumulation of inflammatory cells in response to various stimuli.
IPF je kronična fibrozirajuća i upalna plućna bolest na koju utječu sinteza i otpuštanje proupalnih citokina, uključujući faktor tumorske nekroze-alfa (engl. tumour necrosis factor-alpha, TNF-α) i interleukin-1-beta (IL-1β), a pokazalo se da pirfenidon smanjuje nakupljanje upalnih stanica kao odgovor na različite stimulanse.
IPF is a condition in which the tissue in your lungs becomes thickened, stiff and scarred over time.
IPF je stanje u kojem tkivo u plućima s vremenom postaje zadebljalo, kruto i ožiljkasto.
Ipilimumab 3 mg/kg every
Ipilimumab 3 mg/kg svaka
Ipilimumab clearance increased with increasing body weight and with increasing LDH at baseline; however, no dose adjustment is required for elevated LDH or body weight after administration on a mg/kg basis.
Klirens ipilimumaba povećavao se s povećanjem tjelesne težine i povećanim LDH na početku; međutim, nije potrebno prilagođavati dozu zbog povišene razine LDH ili tjelesne težine nakon primjene na temelju mg/kg.
Ipilimumab has been designed to attach to and block the activity of a protein called CTLA-4 that is found on the surface of T cells, a type of white blood cell.
Ipilimumab je dizajniran za vezanje na i blokiranje djelovanja proteina naziva CTLA-4 koji se nalazi na površini T stanica, tipa bijelih krvnih stanica.
Ipilimumab is a CTLA-4 immune checkpoint inhibitor that blocks T-cell inhibitory signals induced by the CTLA-4 pathway, increasing the number of reactive T-effector cells which mobilize to mount a direct T-cell immune attack against tumour cells.
Ipilimumab je inhibitor imunološke kontrolne točke CTLA-4 koji blokira inhibicijske signale T stanice inducirane CTLA-4 putem, povećavajući broj reaktivnih efektorskih T stanica koje se mobiliziraju kako bi se pokrenuo direktan imunološki napad T stanica protiv tumorskih stanica.
Ipilimumab is a human monoclonal antibody that is not metabolized by cytochrome P450 enzymes (CYPs) or other drug metabolizing enzymes.
Ipilimumab je ljudsko monoklonsko protutijelo koje se ne metabolizira enzimima citokroma P450 (CYP) niti drugi enzimima koji metaboliziraju lijekove.
Ipilimumab is a T-cell potentiator that enables the immune response (see section 5.1) and may interfere with immunosuppressive therapy, resulting in an exacerbation of the underlying disease or increased risk of graft rejection.
Ipilimumab je pojačivač aktivnosti T stanica koji omogućuje imunološki odgovor (vidjeti dio 5.1) i može ometati imunosupresivnu terapiju te tako dovesti do pogoršanja osnovne bolesti ili povećanja rizika odbacivanja presatka.
Ipilimumab is associated with serious immune-related gastrointestinal reactions.
Ipilimumab je povezan s ozbiljnim imunološki uzrokovanim nuspojavama probavnog sustava.
Ipilimumab is associated with serious immune-related neurological adverse reactions.
Ipilimumab se povezuje s ozbiljnim imunološki uzrokovanim nuspojavama živčanog sustava.
Ipilimumab is associated with serious immune-related neurological reactions.
Ipilimumab je povezan s ozbiljnim imunološki uzrokovanim nuspojavama živčanog sustava.
Ipilimumab is associated with serious skin adverse reactions that may be immune-related.
Ipilimumab je povezan s ozbiljnim kožnim nuspojavama koje mogu biti imunološki uzrokovane.
Ipilimumab is used to treat advanced melanoma (a type of skin cancer) in adults.
Ipilimumab se koristi za liječenje uznapredovalog melanoma (vrsta raka kože) u odraslih.
Ipilimumab may selectively deplete T- regulatory cells at the tumour site, leading to an increase in the intratumoral T-effector/ T-regulatory cell ratio which drives tumour cell death.
Ipilimumab može selektivno smanjiti broj regulacijskih T stanica na mjestu tumora što dovodi do povećanja u omjeru intratumorski T efektor/regulacijska T stanica što dovodi do smrti tumorskih stanica.
Ipilimumab must be permanently discontinued in patients with severe (Grade 3 or 4) diarrhoea or colitis (see section 4.2), and systemic high-dose intravenous corticosteroid therapy should be initiated immediately. (In clinical trials, methylprednisolone 2 mg/kg/day has been used).
U bolesnika s teškim (3. ili 4. stupanj) proljevom ili kolitisom (vidjeti dio 4.2) primjena ipilimumaba mora se trajno prekinuti i odmah započeti s intravenskom terapijom visokim dozama sistemskih kortikosteroida. (U kliničkim ispitivanjima koristio se metilprednizolon u dozi od 2 mg/kg/dan).
Ipilimumab must be permanently discontinued in patients with severe (Grade 3 or 4) sensory neuropathy suspected to be related to ipilimumab (see section 4.2).
Primjena ipilimumaba mora se trajno prekinuti u bolesnika s teškom (3. ili 4. stupnja) senzoričkom neuropatijom za koju se vjeruje da je povezana s ipilimumabom (vidjeti dio 4.2).
Ipilimumab, by blocking CTLA-4, leads to the activation and spread of the T cells, which infiltrate tumours and kill the tumour cells.
Blokirajući CTLA-4, ipilimumab uzrokuje aktiviranje i širenje T stanica koje infiltriraju tumore i ubijaju tumorske stanice.
Ipilimumab-specific management guidelines for immune-related adverse reactions are described below.
Niže su opisane posebne smjernice za liječenje imunološki uzrokovanih nuspojava lijeka ipilimumab.
Ipreziv 20 mg tablets
Ipreziv 20 mg tablete
Ipreziv 20 mg tablets azilsartan medoxomil
Ipreziv 20 mg tablete azilsartanmedoksomil
IPREZIV 20 MG TABLETS IPREZIV 40 MG TABLETS IPREZIV 80 MG TABLETS azilsartan medoxomil
IPREZIV 20 MG TABLETE IPREZIV 40 MG TABLETE IPREZIV 80 MG TABLETE azilsartanmedoksomil
Ipreziv 40 mg tablets
Ipreziv 40 mg tablete
Ipreziv 40 mg tablets azilsartan medoxomil
Ipreziv 40 mg tablete azilsartanmedoksomil
Ipreziv 80 mg tablets
Ipreziv 80 mg tablete
Ipreziv 80 mg tablets azilsartan medoxomil
Ipreziv 80 mg tablete azilsartanmedoksomil
Ipreziv are white round tablets debossed “ASL” on one side and either “20”, “40” or “80” on the other.
Ipreziv su bijele okrugle tablete s utisnutom oznakom “ASL” na jednoj strani i “20”, “40” ili “80” na drugoj.
Ipreziv contains an active substance called azilsartan medoxomil and belongs to a class of medicines called angiotensin II receptor antagonists (AIIRAs).
Ipreziv sadrži djelatnu tvar po nazivu azilsartanmedoksomil i pripada skupini lijekova koji se zovu antagonisti receptora angiotenzina II .
Ipreziv is for oral use and may be taken with or without food (see section 5.2).
Ipreziv je namijenjen za peroralnu primjenu i može se uzimati s hranom ili bez nje (vidjeti dio 5.2).
Ipreziv is for oral use and may be taken with or without food (see section 5.2).
Iprezivje namijenjen za peroralnu primjenu i može se uzimati s hranom ili bez nje (vidjeti dio 5.2).
Ipreziv is provided in blister packs with each blister pack having either 14 tablets or 15 tablets within cartons containing:
Ipreziv je pakiran u blister pakiranjima sa 14 tableta ili 15 tableta unutar kutija koje sadrže:
Ipsen Pharma Biotech SAS Parc d‟Activités du Plateau de
Ipsen Pharma Biotech SAS
IPSS
Bolesnika
IPSS is a rating of the patient’s symptoms such as the inability to empty the bladder, and the urge to urinate repeatedly or to strain while urinating.
IPSS predstavlja indeks kojim se vrednuju simptomi bolesnika poput nemogućnosti pražnjenja mjehura i potrebe za učestalim mokrenjem ili naprezanja prilikom mokrenja.
IR = incremental recovery; AUC = area under the factor IX activity time curve; CL = body weight adjusted clearance; Elimination t1/2 = Elimination half-life
AUC = područje ispod krivulje aktivnost vrijeme faktora IX ; CL = klirens prilagođen za tjelesnu težinu;
ir/ ritonavir
aritaprevir/ri
Irbesartan 150 mg film-coated tablets are white to off white capsule shaped, film coated tablet.
Irbesartan 150 mg filmom obložene tablete su bijele do gotovo bijele filmom obložene tablete u obliku kapsule.
Irbesartan 75 mg film-coated tablets are white to off white capsule shaped, film coated tablet.
Irbesartan 75 mg filmom obložene tablete su bijele do gotovo bijele filmom obložene tablete u obliku kapsule.
Irbesartan and hydrochlorothiazide (at doses up to 300 mg irbesartan/25 mg hydrochlorothiazide) have been safely administered with other antihypertensive agents including calcium channel blockers and beta-adrenergic blockers.
Irbesartan i hidroklorotiazid (u dozama do 300 mg irbesartana/25 mg hidroklorotiazida) primjenjivani su sa sigurnošću u kombinaciji s drugim antihipertenzivima uključujući blokatore kalcijevih kanala i blokatore beta- adrenergičkih receptora.
Irbesartan AUC and Cmax values were also somewhat greater in elderly subjects (≥ 65 years) than those of young subjects (18 - 40 years).
Vrijednosti AUC i Cmax irbesartana također su bile nešto veće u starijih ispitanika (≥ 65 godina) u usporedbi s mlađima (18-40 godina).
Irbesartan AUC and Cmax values were also somewhat greater in oldersubjects (≥ 65 years) than those of young subjects (18 - 40 years).
Vrijednosti AUC i Cmax irbesartana također su bile nešto veće u starijih ispitanika (≥ 65 godina) u usporedbi s mlađima (18-40 godina).
Irbesartan AUC and Cmax values were also somewhat greater in oldersubjects (≥ 65 years) than those of young subjects (18-40 years).
Vrijednosti AUC i Cmax irbesartana također su bile nešto veće u starijih (≥ 65 godina) nego u mlađih bolesnika (18 do 40 godina).
Irbesartan AUC and Cmax values were also somewhat greater in oldersubjects (≥ 65 years) than those of young subjects (18-40 years).
Vrijednosti AUC i Cmax irbesartana također su bile nešto veće u starijih ispitanika (≥ 65 godina) u usporedbi s mlađima (18-40 godina).
Irbesartan does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also degrades bradykinin into inactive metabolites.
Irbesartan ne inhibira ACE (kininazu II), enzim koji generira angiotenzin- II te degradira bradikinin u neaktivne metabolite.
Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg.
Farmakokinetika irbesartana je linearna i proporcionalna dozi u rasponu doza od 10 do 600 mg.
Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg.
Irbesartan pokazuje linearnu farmakokinetiku proporcionalnu dozi pri rasponu doza od 10 do 600 mg.
Irbesartan had no effect upon fertility of treated rats and their offspring up to the dose levels inducing the first signs of parental toxicity (see section 5.3).
Irsartan nije imao nikakvog utjecaja na plodnost tretiranih štakora i njihovih potomaka do doza koje induciraju prve znakove roditeljske toksičnosti (vidjeti dio 5.3).
Irbesartan had no effect upon fertility of treated rats and their offspring up to the dose levels inducingthe first signs of parental toxicity (see section 5.3).
Irbesartan nije utjecao na fertilitet tretiranih štakora ili njihovog potomstva sve do onih doza koje izazivaju prve znakove toksičnosti u roditelja (vidjeti dio 5.3).
Irbesartan has been studied in paediatric populations aged 6 to 16 years old but the current data are insufficient to support an extension of the use in children until further data become available (see sections 4.8, 5.1 and 5.2).
Irbesartan je ispitivan na pedijatrijskoj populaciji u dobi od 6 do 16 godina, ali trenutni podaci nisu dostatni da bi podržali proširenje primjene na djecu dok ne budu dostupni i daljnji podaci (vidjeti dijelove 4.8., 5.1. i 5.2.).
Irbesartan Hydrochlorothiazide Zentiva 150 mg/12.5 mg film-coated tablets are peach, biconvex, oval- shaped, with a heart debossed on one side and the number 2875 engraved on the other side.
Irbesartan Hydrochlorothiazide Zentiva 150 mg/12,5 mg filmom obložene tablete su bikonveksne, ovalne tablete boje breskve s utisnutom oznakom srca na jednoj i brojem 2875 na drugoj strani.
Irbesartan Hydrochlorothiazide Zentiva 150 mg/12.5 mg film-coated tablets.
Irbesartan Hydrochlorothiazide Zentiva 150 mg/12,5 mg filmom obložene tablete